GroundRules
Browse US Code
Read the original sections, or search by topic.
- 21 U.S.C. § 360k · State and local requirements respecting devices
- 21 U.S.C. § 360l · Postmarket surveillance
- 21 U.S.C. § 360m · Accredited persons
- 21 U.S.C. § 360n · Priority review to encourage treatments for tropical diseases
- 21 U.S.C. § 360n–1 · Priority review for qualified infectious disease products
- 21 U.S.C. § 360n–2 · Ensuring cybersecurity of devices
- 21 U.S.C. § 360aa · Recommendations for investigations of drugs for rare diseases or conditions
- 21 U.S.C. § 360bb · Designation of drugs for rare diseases or conditions
- 21 U.S.C. § 360cc · Protection for drugs for rare diseases or conditions
- 21 U.S.C. § 360dd · Open protocols for investigations of drugs for rare diseases or conditions
- 21 U.S.C. § 360ee · Grants and contracts for development of drugs for rare diseases and conditions
- 21 U.S.C. § 360ee–1 · FDA rare neurodegenerative disease grant program
- 21 U.S.C. § 360ff · Priority review to encourage treatments for rare pediatric diseases
- 21 U.S.C. § 360ff–1 · Targeted drugs for rare diseases
- 21 U.S.C. § 360hh · Definitions
- 21 U.S.C. § 360ii · Program of control
- 21 U.S.C. § 360jj · Studies by Secretary
- 21 U.S.C. § 360kk · Performance standards for electronic products
- 21 U.S.C. § 360ll · Notification of defects in and repair or replacement of electronic products
- 21 U.S.C. § 360mm · Imports
- 21 U.S.C. § 360nn · Inspection, records, and reports
- 21 U.S.C. § 360oo · Prohibited acts
- 21 U.S.C. § 360pp · Enforcement
- 21 U.S.C. § 360qq · Repealed. Pub. L. 105–362, title VI, § 601(a)(2)(A), Nov. 10, 1998, 112 Stat. 3285
- 21 U.S.C. § 360rr · Federal-State cooperation
- 21 U.S.C. § 360ss · State standards
- 21 U.S.C. § 360aaa to 360aaa–6 · Omitted
- 21 U.S.C. § 360bbb · Expanded access to unapproved therapies and diagnostics
- 21 U.S.C. § 360bbb–0 · Expanded access policy required for investigational drugs
- 21 U.S.C. § 360bbb–0a · Investigational drugs for use by eligible patients
- 21 U.S.C. § 360bbb–1 · Dispute resolution
- 21 U.S.C. § 360bbb–2 · Classification of products
- 21 U.S.C. § 360bbb–3 · Authorization for medical products for use in emergencies
- 21 U.S.C. § 360bbb–3a · Emergency use of medical products
- 21 U.S.C. § 360bbb–3b · Products held for emergency use
- 21 U.S.C. § 360bbb–3c · Expedited development and review of medical products for emergency uses
- 21 U.S.C. § 360bbb–4 · Countermeasure development, review, and technical assistance
- 21 U.S.C. § 360bbb–4a · Priority review to encourage treatments for agents that present national security threats
- 21 U.S.C. § 360bbb–4b · Medical countermeasure master files
- 21 U.S.C. § 360bbb–5 · Critical Path Public-Private Partnerships
- 21 U.S.C. § 360bbb–5a · Emerging technology program
- 21 U.S.C. § 360bbb–6 · Risk communication
- 21 U.S.C. § 360bbb–7 · Notification
- 21 U.S.C. § 360bbb–8 · Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
- 21 U.S.C. § 360bbb–8a · Optimizing global clinical trials
- 21 U.S.C. § 360bbb–8b · Use of clinical investigation data from outside the United States
- 21 U.S.C. § 360bbb–8c · Patient participation in medical product discussion
- 21 U.S.C. § 360bbb–8d · Notification, nondistribution, and recall of controlled substances
- 21 U.S.C. § 360ccc · Conditional approval of new animal drugs for minor use and minor species and certain new animal drugs
- 21 U.S.C. § 360ccc–1 · Index of legally marketed unapproved new animal drugs for minor species
- 21 U.S.C. § 360ccc–2 · Designated new animal drugs for minor use or minor species
- 21 U.S.C. § 360ddd · Definitions
- 21 U.S.C. § 360ddd–1 · Regulation of medical gases
- 21 U.S.C. § 360ddd–2 · Inapplicability of drug fees to designated medical gases
- 21 U.S.C. § 360eee · Definitions
- 21 U.S.C. § 360eee–1 · Requirements
- 21 U.S.C. § 360eee–2 · National standards for prescription drug wholesale distributors
- 21 U.S.C. § 360eee–3 · National standards for third-party logistics providers
- 21 U.S.C. § 360eee–4 · Uniform national policy
- 21 U.S.C. § 360fff · Definitions
- 21 U.S.C. § 360fff–1 · Submission of requests
- 21 U.S.C. § 360fff–2 · Eligibility determinations; data submission; filing
- 21 U.S.C. § 360fff–3 · GRASE determination
- 21 U.S.C. § 360fff–4 · Guidance; other provisions
- 21 U.S.C. § 360fff–5 · Repealed. Pub. L. 116–136, div. A, title III, § 3854(b)(5), Mar. 27, 2020, 134 Stat. 456
- 21 U.S.C. § 360fff–6 · Non-sunscreen time and extent applications
- 21 U.S.C. § 360fff–7 · Report
- 21 U.S.C. § 360fff–8 · Sunset
- 21 U.S.C. § 361 · Adulterated cosmetics
- 21 U.S.C. § 362 · Misbranded cosmetics
- 21 U.S.C. § 363 · Regulations making exemptions
- 21 U.S.C. § 364 · Definitions
- 21 U.S.C. § 364a · Adverse events
- 21 U.S.C. § 364b · Good manufacturing practice
- 21 U.S.C. § 364c · Registration and product listing
- 21 U.S.C. § 364d · Safety substantiation
- 21 U.S.C. § 364e · Labeling
- 21 U.S.C. § 364f · Records
- 21 U.S.C. § 364g · Mandatory recall authority
- 21 U.S.C. § 364h · Small businesses
- 21 U.S.C. § 364i · Exemption for certain products and facilities
- 21 U.S.C. § 364j · Preemption
- 21 U.S.C. § 371 · Regulations and hearings
- 21 U.S.C. § 372 · Examinations and investigations
- 21 U.S.C. § 372a · Transferred
- 21 U.S.C. § 373 · Records
- 21 U.S.C. § 374 · Inspection
- 21 U.S.C. § 374a · Inspections relating to food allergens
- 21 U.S.C. § 375 · Publicity
- 21 U.S.C. § 376 · Examination of sea food on request of packer; marking food with results; fees; penalties
- 21 U.S.C. § 377 · Revision of United States Pharmacopoeia; development of analysis and mechanical and physical tests
- 21 U.S.C. § 378 · Advertising of foods
- 21 U.S.C. § 379 · Confidential information
- 21 U.S.C. § 379a · Presumption of existence of jurisdiction
- 21 U.S.C. § 379b · Consolidated administrative and laboratory facility
- 21 U.S.C. § 379c · Transferred
- 21 U.S.C. § 379d · Automation of Food and Drug Administration
- 21 U.S.C. § 379d–1 · Conflicts of interest
- 21 U.S.C. § 379d–2 · Policy on the review and clearance of scientific articles published by FDA employees
- 21 U.S.C. § 379d–3 · Streamlined hiring authority